Trastuzumab biosimilar - Glenmark Pharmaceuticals

Drug Profile

Trastuzumab biosimilar - Glenmark Pharmaceuticals

Alternative Names: GBR-200

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 29 Aug 2017 Phase-III clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Combination therapy) in India (IV) (CTRI2017-02-007892)
  • 08 Mar 2017 Glenmark Pharmaceuticals plans a phase III trial for Breast cancer (Combination therapy, Metastatic disease, Late-stage disease) in India (CTRI2017-02-007892)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top